DuoCort presents phase II/III data at ENDO in Washington DC June 12th

Tid 10 Juni 2009 – 13 Juni 2009

Plats Washington DC, USA

ENDO 09, The Endocrine Society's Annual Meeting, offers an unparalleled opportunity to learn about the latest advances in endocrine research and clinical care, while networking and collaborating with more than 7,500 colleagues from around the world. Wednesday, June 10 through Saturday, June 13, 2009

Kategorier

  • fas ii/iii data
  • endo
  • duocort
  • endo 09

Relaterat innehåll

Lyckad svensk fas II/III studie för ny behandling av Addisons sjukdom

Helsingborg / Washington DC 12 juni 2009- Svenska företaget DuoCort har fått lovande data från sin fas II/III studie för den ovanliga och livshotande Addisons sjukdom. DuoCorts nya mer fysiologiska behandlingsform med hydrokortison givet en gång om dagen visar förbättrade riskfaktorer för hjärt-kärlsjukdom jämfört med dagens standardbehandling med hydrokortison som ofta ges tre gånger om dagen.

Successful phase II/III trial of new therapy for Addison´s disease

Helsingborg/ Washington DC June 12th 2009- DuoCort gained promising data from its Phase II/III study for the rare and life threatening disease adrenal insufficiency. DuoCort’s new form of physiological treatment with once daily dosing show improved cardiovascular measures compared to standard hydrocortisone given thrice daily. The company presents the data at the ENDO congress in Washington DC.